×
S&P 500   3,885.28 (+1.05%)
DOW   31,291.83 (+0.82%)
QQQ   289.71 (+0.32%)
AAPL   144.15 (+0.86%)
MSFT   266.64 (+0.16%)
META   171.07 (+0.77%)
GOOGL   2,324.32 (+1.43%)
AMZN   114.84 (+0.45%)
TSLA   707.87 (+1.82%)
NVDA   154.94 (+2.41%)
NIO   22.21 (+6.63%)
BABA   122.47 (+2.81%)
AMD   77.31 (+2.60%)
MU   59.04 (+2.91%)
T   21.20 (+0.52%)
GE   62.29 (+1.17%)
F   11.54 (+4.34%)
DIS   96.98 (+0.94%)
AMC   12.88 (+2.47%)
PFE   53.19 (+0.83%)
PYPL   73.88 (+0.87%)
NFLX   187.71 (+1.98%)
S&P 500   3,885.28 (+1.05%)
DOW   31,291.83 (+0.82%)
QQQ   289.71 (+0.32%)
AAPL   144.15 (+0.86%)
MSFT   266.64 (+0.16%)
META   171.07 (+0.77%)
GOOGL   2,324.32 (+1.43%)
AMZN   114.84 (+0.45%)
TSLA   707.87 (+1.82%)
NVDA   154.94 (+2.41%)
NIO   22.21 (+6.63%)
BABA   122.47 (+2.81%)
AMD   77.31 (+2.60%)
MU   59.04 (+2.91%)
T   21.20 (+0.52%)
GE   62.29 (+1.17%)
F   11.54 (+4.34%)
DIS   96.98 (+0.94%)
AMC   12.88 (+2.47%)
PFE   53.19 (+0.83%)
PYPL   73.88 (+0.87%)
NFLX   187.71 (+1.98%)
S&P 500   3,885.28 (+1.05%)
DOW   31,291.83 (+0.82%)
QQQ   289.71 (+0.32%)
AAPL   144.15 (+0.86%)
MSFT   266.64 (+0.16%)
META   171.07 (+0.77%)
GOOGL   2,324.32 (+1.43%)
AMZN   114.84 (+0.45%)
TSLA   707.87 (+1.82%)
NVDA   154.94 (+2.41%)
NIO   22.21 (+6.63%)
BABA   122.47 (+2.81%)
AMD   77.31 (+2.60%)
MU   59.04 (+2.91%)
T   21.20 (+0.52%)
GE   62.29 (+1.17%)
F   11.54 (+4.34%)
DIS   96.98 (+0.94%)
AMC   12.88 (+2.47%)
PFE   53.19 (+0.83%)
PYPL   73.88 (+0.87%)
NFLX   187.71 (+1.98%)
S&P 500   3,885.28 (+1.05%)
DOW   31,291.83 (+0.82%)
QQQ   289.71 (+0.32%)
AAPL   144.15 (+0.86%)
MSFT   266.64 (+0.16%)
META   171.07 (+0.77%)
GOOGL   2,324.32 (+1.43%)
AMZN   114.84 (+0.45%)
TSLA   707.87 (+1.82%)
NVDA   154.94 (+2.41%)
NIO   22.21 (+6.63%)
BABA   122.47 (+2.81%)
AMD   77.31 (+2.60%)
MU   59.04 (+2.91%)
T   21.20 (+0.52%)
GE   62.29 (+1.17%)
F   11.54 (+4.34%)
DIS   96.98 (+0.94%)
AMC   12.88 (+2.47%)
PFE   53.19 (+0.83%)
PYPL   73.88 (+0.87%)
NFLX   187.71 (+1.98%)
NASDAQ:MNKD

MannKind Stock Forecast, Price & News

$4.12
+0.07 (+1.73%)
(As of 07/6/2022 12:00 AM ET)
Add
Compare
Today's Range
$4.01
$4.37
50-Day Range
$2.67
$4.77
52-Week Range
$2.49
$5.44
Volume
5.51 million shs
Average Volume
5.71 million shs
Market Capitalization
$1.04 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.00

MannKind MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
45.6% Upside
$6.00 Price Target
Short Interest
Bearish
16.19% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.34) to ($0.13) Per Share

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

1.60 out of 5 stars

Medical Sector

786th out of 1,433 stocks

Pharmaceutical Preparations Industry

399th out of 683 stocks

30 days | 90 days | 365 days | Advanced Chart

Receive MNKD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MannKind and its competitors with MarketBeat's FREE daily newsletter.

MannKind logo

About MannKind (NASDAQ:MNKD) Stock

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocrinologists, and other healthcare providers for the treatment of hypothyroidism. The company has a license and collaboration agreement with United Therapeutics Corporation. It also has an agreement with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), a synthetic form of human vasoactive intestinal peptide to help protect cells against inflammatory conditions. MannKind Corporation was incorporated in 1991 and is headquartered in Westlake Village, California.

MNKD Stock News Headlines

MannKind (NASDAQ:MNKD) Stock Price Down 5.6%
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:MNKD
CUSIP
56400P20
Employees
348
Year Founded
1991

Company Calendar

Last Earnings
5/05/2022
Today
7/07/2022
Next Earnings (Estimated)
8/10/2022
Fiscal Year End
12/31/2022

Price Target and Rating

Average Stock Price Forecast
$6.00
High Stock Price Forecast
$6.00
Low Stock Price Forecast
$6.00
Forecasted Upside/Downside
+45.6%
Consensus Rating
Buy
Rating Score (0-4)
3
Research Coverage
3 Analysts

Profitability

Net Income
$-80,930,000.00
Net Margins
-134.30%
Pretax Margin
-134.30%

Debt

Sales & Book Value

Annual Sales
$75.44 million
Book Value
($0.83) per share

Miscellaneous

Free Float
246,756,000
Market Cap
$1.04 billion
Optionable
Optionable
Beta
1.90

Social Links















MannKind Frequently Asked Questions

Should I buy or sell MannKind stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for MannKind in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" MannKind stock.
View analyst ratings for MannKind
or view top-rated stocks.

What is MannKind's stock price forecast for 2022?

3 analysts have issued 12 month price targets for MannKind's shares. Their MNKD stock forecasts range from $6.00 to $6.00. On average, they expect MannKind's share price to reach $6.00 in the next year. This suggests a possible upside of 45.6% from the stock's current price.
View analysts' price targets for MannKind
or view top-rated stocks among Wall Street analysts.

How has MannKind's stock performed in 2022?

MannKind's stock was trading at $4.37 at the beginning of the year. Since then, MNKD stock has decreased by 5.7% and is now trading at $4.12.
View the best growth stocks for 2022 here
.

When is MannKind's next earnings date?

MannKind is scheduled to release its next quarterly earnings announcement on Wednesday, August 10th 2022.
View our earnings forecast for MannKind
.

How were MannKind's earnings last quarter?

MannKind Co. (NASDAQ:MNKD) posted its quarterly earnings results on Thursday, May, 5th. The biopharmaceutical company reported ($0.10) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.10). The biopharmaceutical company earned $11.99 million during the quarter, compared to the consensus estimate of $10.44 million. During the same period last year, the firm posted ($0.05) earnings per share.
View MannKind's earnings history
.

Who are MannKind's key executives?

MannKind's management team includes the following people:
  • Dr. Michael E. Castagna Pharm.D., CEO & Director (Age 45, Pay $1.12M)
  • Mr. Steven B. Binder, Chief Financial Officer (Age 59, Pay $772.05k) (LinkedIn Profile)
  • Mr. Joseph Kocinsky M.B.A., M.S., Chief Technology Officer (Age 58, Pay $608.75k)
  • Dr. David B. Thomson, Exec. VP, Gen. Counsel & Sec. (Age 55, Pay $772.9k) (LinkedIn Profile)
  • Dr. Stuart A. Tross Ph.D., Chief People & Workplace Officer (Age 55, Pay $652.85k)
  • Mr. Thomas Hofmann M.D., Ph.D., Chief Scientific Officer
  • Ms. Rosabel Realica Alinaya, VP of Investor Relations & Treasury (Age 61)
  • Mr. John F. Bedard, Sr. VP of Worldwide Regulatory Affairs (Age 72)
  • Mr. James Patrick McCauley Jr., J.D., M.B.A., Chief Commercial Officer (Age 56)
  • Mr. Alejandro Galindo M.B.A., M.S., Exec. VP of Endocrine Bus. Unit (Age 50) (LinkedIn Profile)

What other stocks do shareholders of MannKind own?

Based on aggregate information from My MarketBeat watchlists, some companies that other MannKind investors own include Bausch Health Companies (BHC), Novavax (NVAX), Geron (GERN), ACADIA Pharmaceuticals (ACAD), Advanced Micro Devices (AMD), Chesapeake Energy (CHKAQ), Micron Technology (MU), NVIDIA (NVDA), Intel (INTC) and Gilead Sciences (GILD).

What is MannKind's stock symbol?

MannKind trades on the NASDAQ under the ticker symbol "MNKD."

How do I buy shares of MannKind?

Shares of MNKD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is MannKind's stock price today?

One share of MNKD stock can currently be purchased for approximately $4.12.

How much money does MannKind make?

MannKind (NASDAQ:MNKD) has a market capitalization of $1.04 billion and generates $75.44 million in revenue each year. The biopharmaceutical company earns $-80,930,000.00 in net income (profit) each year or ($0.37) on an earnings per share basis.

How many employees does MannKind have?

MannKind employs 348 workers across the globe.

When was MannKind founded?

MannKind was founded in 1991.

How can I contact MannKind?

MannKind's mailing address is 30930 RUSSELL RANCH ROAD SUITE 300, WESTLAKE VILLAGE CA, 91362. The official website for MannKind is www.mannkindcorp.com. The biopharmaceutical company can be reached via phone at (818) 661-5000, via email at ir@mannkindcorp.com, or via fax at 661-775-2081.

This page (NASDAQ:MNKD) was last updated on 7/7/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.